Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
14.05
+0.06 (0.43%)
At close: Apr 1, 2025, 4:00 PM
14.04
-0.01 (-0.06%)
After-hours: Apr 1, 2025, 5:15 PM EDT

Inhibrx Biosciences Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Cash & Equivalents
152.6277.92-
Cash & Short-Term Investments
152.6277.92-
Cash Growth
-45.09%--
Accounts Receivable
0.40.780.24
Other Receivables
0.02-0.01
Receivables
0.420.780.26
Inventory
29.890.81
Prepaid Expenses
4.195.674.53
Other Current Assets
1.21.090.67
Total Current Assets
160.4295.366.26
Property, Plant & Equipment
13.549.377.22
Other Long-Term Assets
6.833.163.16
Total Assets
180.77307.8916.65
Accounts Payable
14.8933.769.45
Accrued Expenses
24.2520.499.46
Current Portion of Leases
1.62.061.86
Total Current Liabilities
40.7356.3120.77
Long-Term Debt
-206.97-
Long-Term Leases
6.451.113.17
Total Liabilities
47.18264.3923.95
Common Stock
00.01-7.3
Additional Paid-In Capital
239.72657.23-
Retained Earnings
-106.13-613.73-
Shareholders' Equity
133.5843.5-7.3
Total Liabilities & Equity
180.77307.8916.65
Total Debt
8.05210.145.03
Net Cash (Debt)
144.5567.78-5.03
Net Cash Growth
113.25%--
Net Cash Per Share
9.655.75-
Filing Date Shares Outstanding
14.4811.78-
Total Common Shares Outstanding
14.4811.78-
Working Capital
119.67239.05-14.51
Book Value Per Share
9.233.69-
Tangible Book Value
133.5843.5-7.3
Tangible Book Value Per Share
9.233.69-
Machinery
10.319.027.55
Construction In Progress
-3.59-
Leasehold Improvements
0.80.440.44
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q